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Diagnostic accuracy of point-of-care testing for acute coronary
syndromes, heart failure and thromboembolic events in primary
care:a cluster-randomised controlled trial
Abstract
Abstract Background: Evidence of the clinical benefit of 3-in-1 point-of-care testing (POCT) for cardiac
troponin T (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP) and D-dimer in
cardiovascular risk stratification at primary care level for diagnosing acute coronary syndromes (ACS),
heart failure (HF) and thromboembolic events (TE) is very limited. The aim of this study is to analyse
the diagnostic accuracy of POCT in primary care. Methods: Prospective multicentre controlled trial
cluster-randomised to POCT-assisted diagnosis and conventional diagnosis (controls). Men and women
presenting in 68 primary care practices in Zurich County (Switzerland) with chest pain or symptoms of
dyspnoea or TE were consecutively included after baseline consultation and working diagnosis. A
follow-up visit including confirmed diagnosis was performed to determine the accuracy of the working
diagnosis, and comparison of working diagnosis accuracy between the two groups. Results: The 218
POCT patients and 151 conventional diagnosis controls were mostly similar in characteristics,
symptoms and pre-existing diagnoses, but differed in working diagnosis frequencies. However, the
follow-up visit showed no statistical intergroup difference in confirmed diagnosis frequencies. Working
diagnoses overall were significantly more correct in the POCT group (75.7% vs 59.6%, p = 0.002), as
were the working diagnoses of ACS/HF/TE (69.8% vs 45.2%, p = 0.002). All three biomarker tests
showed good sensitivity and specificity. Conclusion: POCT confers substantial benefit in primary care
by correctly diagnosing significantly more patients.
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Abstract
Background: Evidence of the clinical benefit of 3-in-1 point-of-care testing (POCT) for cardiac troponin T (cTnT),
N-terminal pro-brain natriuretic peptide (NT-proBNP) and D-dimer in cardiovascular risk stratification at primary care
level for diagnosing acute coronary syndromes (ACS), heart failure (HF) and thromboembolic events (TE) is very
limited. The aim of this study is to analyse the diagnostic accuracy of POCT in primary care.
Methods: Prospective multicentre controlled trial cluster-randomised to POCT-assisted diagnosis and conventional
diagnosis (controls). Men and women presenting in 68 primary care practices in Zurich County (Switzerland) with
chest pain or symptoms of dyspnoea or TE were consecutively included after baseline consultation and working
diagnosis. A follow-up visit including confirmed diagnosis was performed to determine the accuracy of the
working diagnosis, and comparison of working diagnosis accuracy between the two groups.
Results: The 218 POCT patients and 151 conventional diagnosis controls were mostly similar in characteristics,
symptoms and pre-existing diagnoses, but differed in working diagnosis frequencies. However, the follow-up visit
showed no statistical intergroup difference in confirmed diagnosis frequencies. Working diagnoses overall were
significantly more correct in the POCT group (75.7% vs 59.6%, p = 0.002), as were the working diagnoses of
ACS/HF/TE (69.8% vs 45.2%, p = 0.002). All three biomarker tests showed good sensitivity and specificity.
Conclusion: POCT confers substantial benefit in primary care by correctly diagnosing significantly more patients.
Trial registration: DRKS: DRKS00000709
Background
Chest pain, tightness, pressure or squeezing, along with
dyspnoea and heartburn-like sensations, are a diagnostic
challenge in primary care medicine. Symptoms are often
an inadequate guide to a working diagnosis. Common
causes of chest pain and dyspnoea include stable angina,
gastrointestinal disease, panic disorder, viral infection
and musculoskeletal pain, but the most serious suspects
include acute coronary syndromes (ACS), heart failure
(HF) and thromboembolic events (TE) [1-3].
Numerous cardiovascular biomarkers are now avail-
able [4]. Cardiac troponin T (cTnT), N-terminal pro-
brain natriuretic peptide (NT-proBNP) and D-dimer are
the most used, in particular for cardiovascular risk stra-
tification [5]. New multifunctional devices measure all
three in minutes.
cTnT is a highly specific and sensitive protein for
diagnosing myocardial necrosis: elevation diagnoses ACS
and identifies patients at high risk of cardiac events [6].
NT-proBNP differentiates cardiac from non-cardiac
causes of dyspnoea and excludes HF in symptomatic
patients [7]. As reported by Jernberg et al. [8], NT-
proBNP analysis improves the early detection of patients
with potential ACS and non ST-segment elevation
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myocardial infarction (NSTEMI). NT-proBNP elevation
also has high prognostic value, being associated with
increased mortality in cardiovascular patients [9]. The
strength of D-dimer, an indicator of fibrin degradation
and coagulation activation, lies in its high negative pre-
dictive value (NPV) for excluding TE (deep vein throm-
bosis [DVT] and pulmonary embolism [PE]) [10]. Its
specificity is usually low since increased levels are
encountered in many non-thrombotic situations [11].
Our aim was to analyse the benefit of POCT for cardi-
ovascular risk stratification in primary care. We
hypothesised that POCT testing for cTnT, NT-proBNP,
and/or D-dimer in venous whole blood would allow for
a more accurate diagnosis of ACS, HF and TE by office-
based, Swiss general practitioners.
Methods
Patients and study design
We randomised 68 primary care practices in Zurich
County (Switzerland) to diagnostic aid from a POCT
analyser (n = 33 [39 physicians]; POCT group) or to
conventional diagnosis employing best clinical practice
(n = 35 [40 physicians]; controls). We randomised only
practices at least 8-10 km from Zurich and Winterthur
where laboratories with specialised diagnostic systems
are less available.
All patients presenting with potentially cardiovascular
chest pain or symptoms between May 2006 and August
2007 were invited to participate. Patients gave written
informed consent and the study received approval from
the cantonal ethics committee (Kantonale Ethikkommis-
sion Zürich), in line with the Declaration of Helsinki
(1996) and Good Clinical Practice guidelines. Non-inclu-
sion criteria were refusal of consent, presentation >5
days after symptom onset, recent anticoagulant treat-
ment, severe renal dysfunction and cancer therapy.
Rationales for the exclusion criteria were the normalisa-
tion of the cTnT level five days after ACS, the fact that
cTnT may be increased even in the absence of clinically
suspected acute myocardial ischemia in patients with
renal insufficiency, and the unpredictable effect of antic-
oagulant treatment and cancer therapy on the biomar-
kers’ concentration [12,13].
Physicians examined all patients before making a
working diagnosis of ACS, HF, TE, musculoskeletal or
“other” (specified) problems based on the patients char-
acteristics, medical history, symptoms, physical findings
and, in the POCT group, the biomarkers (it was not
mandatory to analyse all biomarkers: the physicians had
the possibility to choose if and which biomarker test
was necessary). At follow-up 3 weeks later the same
physician reviewed the working diagnosis. The follow-up
diagnosis was defined as the confirmed diagnosis. Fol-
low-up data of patients requiring additional specialist
visits or hospitalisation were provided by specialist or
hospital reports.
Technical information
POCT practices received a bedside Cardiac Reader®
(Roche Diagnostics, Switzerland), a 3-in-1 device that
determines cTnT, NT-proBNP or D-dimer in heparinised
venous whole blood within 8-12 min. Measurement
was quantitative for each parameter over the ranges 0.05-
2.00 ng/ml, 60-3000 pg/ml and 0.1-4.0 μg/ml, with vali-
dated positive/negative cut-offs of 0.1 ng/ml, 125 pg/ml
and 0.5 μg/ml. Instruction to the POC-instrument always
was performed by the same specialist from Roche Diag-
nostic. All GPs who received a POCT device received
advice on the interpretation of test results. Test quality
was monitored using the internal and external quality
controls required by Swiss federal law and the Swiss
Commission for Quality Assurance in the Medical
Laboratory (QUALAB) [14].
Statistical analysis
Data were analysed using SPSS 14.0 for Windows. Inter-
group comparisons of categorical data were performed
using univariate logistic regression; standard errors and
p values were adjusted for the effect of clustering utilis-
ing a generalised estimating equations approach. We
detected an interclass correlation coefficient of 0.073 for
the main binary endpoint of a correct versus incorrect
working diagnosis.
To evaluate diagnostic test quality and performance
we plotted receiver operating characteristic (ROC)
curves, defined as plots of test sensitivity on the y axis
vs. 1-specificity on the × axis. The area under the ROC
curve (AUC) combining sensitivity and specificity was
used to measure overall diagnostic test performance and
was interpreted as the average sensitivity value for all
possible specificity values.
Results
Study population
Of the 369 patients recruited, 218 (59%) were enrolled
in the POCT group (7 ± 10/practice) and 151 (41%) in
the control group (4 ± 4/practice). Characteristics and
blood parameters were similar in both groups (Table 1).
The interval between symptom onset and baseline visit
was much longer in the POCT group because some
(mainly POCT) patients presented over 5 days after
symptom onset (non-inclusion criterion). We contacted
the practices for specific explanations. In almost all cases
the patients had visited the physician in the previous
weeks/months (> > 5 days) with similar problems. Due to
new or exacerbated symptoms (onsetting in the previous
5 days) they revisited their physician who reported the
date of their first or previous visit incorrectly. After
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patients with incorrect symptom onset were excluded,
the average interval between symptom onset and baseline
visit became similar in the two groups.
Presenting symptoms
Many patients reported mixed sensations of pain or dis-
comfort. Both groups had high prevalence of acute chest
pain, tightness, pressure or squeezing, dyspnoea and
heartburn-like sensations. Other symptoms were rela-
tively rare (Table 2). The groups statistically differed in
rates of acute chest and calf pain.
Medical history
The most frequent pre-existing diagnoses were hyper-
tension, diabetes and angina. Only the proportion of
patients with previously diagnosed HF differed substan-
tially between the groups (Table 3). Pathological electro-
cardiograms (ECGs) were more prevalent in controls.
Reasons for hospitalisation in the previous 12 months
were diverse and only partially cardiovascular.
Working and confirmed diagnoses
Some working diagnoses differed in frequency between
the groups (Figure 1). In the POCT group ACS was less
frequent, and HF more frequent, than in controls (p =
0.03 and p = 0.04). TE was similar in frequency (p =
0.81), as were musculoskeletal problems (p = 0.34) and
“other” diagnoses (e.g. stable angina, pleuritis, psychia-
tric problems, viral infection; p = 0.97).
However, confirmed diagnoses did not differ in fre-
quency (Figure 2). Intergroup ACS and TE were similar
Table 1 Baseline demographics, clinical chemistry and interval between symptom onset and baseline presentation
Variable POCT
(n = 218)
Controls (n = 151)
n (%)
or mean ± SD
n (%)
or mean ± SD
Men 121 (57.9) 83 (58.0)
Age [years] 65 ± 16 64 ± 17
Weight [kg] 80 ± 17 78 ± 17
Height 169 ± 10 169 ± 9
Body mass index [kg/m2] 28 ± 5 27 ± 6
Glucose [mmol/l] 5.9 ± 1.5 6.3 ± 2.1
Creatinine [mmol/l] 84.4 ± 29.1 84.4 ± 22.4
High-density lipoprotein [mmol/l] 1.4 ± 0.7 1.4 ± 0.5
Low-density lipoprotein [mmol/l] 2.9 ± 1.0 3.3 ± 1.0
Triglycerides [mmol/l] 1.7 ± 1.1 1.7 ± 1.0
Interval between symptom onset and baseline visit [all patients, days] 3.3 ± 9.8 1.7 ± 1.7
Interval between symptom onset and baseline visit [patients presenting <5 days after symptom onset, days] 1.2 ± 1.4
(n = 185)
1.5 ± 1.4
(n = 141)
POCT, point-of-care testing; SD, standard deviation.
Table 2 Presenting symptoms
Symptoms POCT (n = 218)
n (%)
Controls (n = 151)
n (%)
Acute chest pain 99 (45) 96 (64)
Tightness, pressure, or
squeezing in the chest
138 (63) 92 (61)
Dyspnoea 99 (45) 69 (46)
Heartburn-like sensation 32 (15) 19 (13)
Heaviness and tension
sensations in the leg
16 (7) 5 (3)
Calf pain 16 (7) 4 (3)
Neck vein congestion 4 (2) 4 (3)
Oedema 22 (10) 9 (6)
Nocturia 7 (3) 4 (3)
Cyanosis 2 (1) 3 (2)
Table 3 Medical history
POCT (n = 218)
n (%)
Controls (n = 151)
n (%)
Malignant tumour 15 (7) 7 (5)
Thrombosis/embolism 12 (6) 13 (9)
Myocardial infarction 15 (7) 11 (7)
Heart failure 19 (9) 5 (3)
Angina 20 (9) 15 (10)
Renal failure 13 (6) 8 (5)
Diabetes 34 (16) 15 (10)
Aneurysm/dissection 1 (1) 2 (1)
Hypertension 48 (22) 23 (15)
Chronic obstructive
pulmonary disease
9 (4) 5 (3)
Peripheral arterial disease 10 (5) 5 (3)
Smokers 35 (16) 24 (16)
Pathological
electrocardiogram
71 (33) 59 (39)
Hospitalisation in previous 12
months
43 (20) 25 (17)
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(p = 0.87 and p = 0.93), while HF remained substan-
tially, but non-significantly, more frequent in the POCT
group (p = 0.08). In both groups, two-thirds of patients
had musculoskeletal problems (p = 0.49) or “other”
diagnoses (p = 0.57).
Diagnostic accuracy of the working diagnosis
In the POCT group 165/218 working diagnoses (76%)
proved correct vs 90/151 (60%) in controls (p = 0.002).
Seventy percent of the working diagnoses of ACS, HF
and TE proved correct in the POCT group vs 45% in
POCT Controls
ACS HF TE MS HF+TE ACS+HF Oth er
Working diagnoses
5 %
1 0%
1 5%
2 0%
2 5%
Pe
rc
en
t
n =3 2 n =4 3 n =1 9 n =6 2 n =1 n =1 n =6 0
ACS HF TE MS HF+TE ACS+HF Oth er
Working diagnoses
n =4 3 n =1 4 n =1 5 n =3 6 n =1 n =4 2
Figure 1 Working diagnoses at baseline. ACS diagnoses were more frequent, and HF diagnoses less frequent, in controls (p = 0.03 and p =
0.04). TE diagnoses were similar in both groups (p = 0.81). One patient per group was diagnosed with both ACS and HF, and one POCT patient
with both HF and TE. Most diagnoses in both groups were musculoskeletal or “other” problems (p = 0.35 and p = 0.97). (ACS, acute coronary
syndromes; HF, heart failure; MS, musculoskeletal problems; TE, thromboembolic events).
POCT Controls
ACS HF TE MS HF+T E Other
Confirmed diagnoses
10%
20%
30%
40%
Pe
rc
en
t
n=19 n=38 n=13 n=66 n=1 n=81
ACS HF TE MS HF+T E Other
Confirmed diagnoses
n=14 n=12 n=10 n=53 n=62
Figure 2 Confirmed diagnoses. The incidences of ACS and TE were similar in both groups (p = 0.87 and p = 0.93). HF appeared more
frequent in the POCT group but the difference was nonsignificant (p = 0.08). Musculoskeletal and “other” problems were the predominant
diagnoses (p = 0.49 and p = 0.57). (ACS, acute coronary syndromes; HF, heart failure; MS, musculoskeletal problems; TE, thromboembolic events).
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the controls (p = 0.002), with false-positives in 29 (30%)
patients vs 40 (55%) patients, respectively. In contrast,
correctness of the remaining working diagnoses (muscu-
loskeletal or “other” problems) did not differ: 80% in the
POCT group vs 73% in the controls (p = 0.31).
Except for ACS, where sensitivity was higher in con-
trols, working diagnoses were more sensitive in the
POCT group (Table 4). However, specificity was similar
in both groups, except for ACS, where it was higher in
the POCT group. NPVs of the ACS, HF, and TE diag-
noses were near-identical. Overall these results con-
firmed greater diagnostic accuracy in the POCT group.
Biomarker performance in the POCT group
Individual test sensitivities and NPVs were generally
higher when assessed using the confirmed diagnoses.
Specificities, in contrast, differed only marginally.
The diagnostic power of the cTnT test was higher
when assessed using the confirmed diagnoses: sensitivity
and NPV were 17% and 6% higher (Table 5). Seven
patients had a false-negative result and risked a wrong
diagnosis. Two had a history of myocardial infarction and
were polymedicated (statins, aspirin, diuretics, b-block-
ers); based on their history and medication they were
correctly diagnosed with ACS. Another had a history of
angina and was polymedicated: recurrent angina was sus-
pected. A patient presenting 5 hours after symptom
onset was diagnosed with stable angina. The final three
patients were diagnosed correctly from their symptoms.
The diagnostic power of the NT-proBNP tests was
high: all patients with HF also had a positive NT-proBNP,
and while none of those with a negative NT-proBNP had
HF. Specificity was 72%.
The D-dimer test had a sensitivity of 93%, specificity
of 78% and NPV of 99%. The single false-negative was
in a 65-year-old man with a history of cancer who was
correctly diagnosed with deep vein thrombosis from his
symptoms.
The cTnT ROC curve based on the confirmed diag-
noses was somewhat oddly shaped because physicians
often recorded the result simply as positive or negative
(< 0.1 ng/ml). In such cases positive and negative cTnT
values were arbitrarily entered as 0.1 ng/ml and 0.0 ng/
ml. Very high test specificity accounted for the mea-
sured AUC, 82% (Figure 3). The NT-proBNP and D-
dimer ROC curves were more regular, achieving high
sensitivity and specificity, with AUCs of 94% and 93%.
Discussion
Our results emphasise the clinical value of POCT using a
novel cardiovascular marker device measuring cTnT,
NT-proBNP and D-dimer for the risk stratification of
ACS, HF and TE in primary care. Diagnoses were more
accurate in the POCT group. In particular, POCT-
assisted physicians avoided numerous false-positive ACS,
HF, and TE diagnoses. This evidence supports the use of
cTnT, NT-proBNP and D-dimer in diagnosing patients
with chest pain or other potentially cardiovascular symp-
toms. Analysis of these biomarkers provides clinical ben-
efit by more accurately ruling in/out ACS, HF and TE,
each with significant management implications.
ACS diagnosis
In previous studies, atypical or absent chest pain has
been associated with failure to recognise ACS by either
physician or patient in up to one third of cases [15].
Our study shows a reverse tendency: the number of
working diagnoses of ACS was unexpectedly high, in
particular in controls. Perhaps the study topic alerted
physicians to ACS as a possible cause of chest pain,
causing them to overestimate its incidence, in particular
in the unassisted control group. Many working diag-
noses were overturned on follow-up, resulting in very
high sensitivity and low specificity. In contrast, the
POCT group suspected fewer ACS, resulting in high
sensitivity and specificity. Despite two false-negatives in
patients wrongly suspected of having stable angina,
POCT was more accurate in stratification: ACS was cor-
rectly ruled in/out in 92% of POCT patients vs 78% of
controls.
Overall, these findings support the notion that when
combined with clinical symptoms and ECG screening,
troponin assay improves diagnostic accuracy, in line
with American College of Cardiology/American Heart
Association guidelines on managing patients with
unstable angina or NSTEMI [16]. Except for the sensi-
tivity results discussed above, our data reflect the 94%
sensitivity and 97% NPV of the cTnT test for ACS
reported by Lüscher et al. [17] in 92 patients with chest
pain, and the 100% sensitivity, 42% specificity and 100%
Table 4 Diagnostic accuracy of the working diagnoses -
sensitivity, specificity and NPV
Sensitivity Specificity NPV
n % n % n %
ACS POCT 17/19 90 183/199 92 183/185 99
Controls 14/14 100 107/137 78 107/107 100
HF POCT 39/39 100 173/179 97 173/173 100
Controls 10/12 83 134/139 96 134/136 99
TE POCT 14/14 100 198/204 97 198/198 100
Controls 9/10 90 135/141 96 135/136 99
MS POCT 54/66 82 144/152 95 144/156 92
Controls 34/53 64 96/98 98 96/115 84
Other POCT 55/81 68 132/137 96 132/158 84
Controls 37/62 60 84/89 94 84/109 77
(i) ACS, acute coronary syndromes; HF, heart failure; MS, musculoskeletal
problems; NPV, negative predictive value; TE, thromboembolic events.
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NPV reported by Fehr et al. [18] in a cross-sectional
study of asymptomatic haemodialysis patients. In our
study, the high AUC value of the cTnT ROC curve, a
measure of overall quality, was largely due to the very
high test specificity. To rule out ACS on the basis of
cTnT, a minimum of 5 hours (time to increase above
the reference range) and a maximum of 5-7 days (time
for biomarker level normalisation) must normally elapse
after symptom onset. Table 1 confirms that most
patients complied with these time limits.
The cTnT assay itself yielded seven false-negatives.
Most patients concerned (5/7) were correctly diagnosed
from their history and symptoms. Recurrent angina was
suspected in the other two patients. High drug con-
sumption in three patients, and the short interval (5 h)
between symptom onset and presentation in one patient,
may partially explain the false-negatives. Misuse of the
POCT device may account for the other cases. That the
same practice made 4/7 false-negative diagnoses sup-
ports this explanation, highlighting the importance of
adequate training on POCT devices. In our study, train-
ing on the POCT instrument always was performed by
the same Roche Diagnostics specialist, but some staff
members were instructed by their colleagues only.
HF diagnosis
HF is a common and increasing public health problem
[19]. Diagnosis in the primary care setting can be diffi-
cult and incorrect in up to 70% of cases [20]. Echocar-
diography is the gold standard for identifying and
confirming left ventricular systolic dysfunction [21] but
is relatively expensive and generally beyond the
resources of general practitioners [22,23]. Even where
available, its appropriate use requires extensive training
and experience.
In our study, diagnosis of HF in the POCT group
showed high sensitivity, specificity and NPV. Sensitivity
in the controls was relatively low, but both specificity and
NPV were high. These results indicate that HF was better
identified in the POCT group, presumably because of the
NT-proBNP data. Assay sensitivity and NPV were per-
fect: all patients with HF had elevated NT-proBNP
values, whereas HF was correctly excluded in all patients
with normal values. The very high AUC of the NT-
proBNP ROC curve (Figure 3) reflects the test’s high
diagnostic accuracy. These results confirm earlier studies:
the NZ prospective Natriuretic Peptides in the Commu-
nity Study, a randomised controlled trial of the effect of
NT-proBNP on HF diagnostic accuracy in primary care,
Table 5 Sensitivity, specificity and NPV of cardiovascular biomarkers in relation to the working and confirmed
diagnoses
Biomarker Working/Confirmed diagnosis Sensitivity Specificity NPV
n % n % n %
cTnT Working ACS 11/26 42 113/121 93 113/128 88
Confirmed ACS 10/17 59 121/130 93 121/128 95
NT-proBNP Working HF 33/35 94 26/35 74 26/28 93
Confirmed HF 31/31 100 28/39 72 28/28 100
D-dimer Working TE 16/20 80 78/98 80 78/82 95
Confirmed TE 13/14 93 81/104 78 81/82 99
(i) ACS, acute coronary syndromes; cTnT, cardiac troponin T; HF, heart failure; NPV, negative predictive value; NT-proBNP, N-terminal pro-brain natriuretic peptide;
TE, thromboembolic events.
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Figure 3 cTnT (left), NT-proBNP (centre) and D-dimer (right) ROC curves. X-axis: 1-Specificity; Y-axis: Sensitivity. Areas under the curve (AUC):
82% (95% confidence interval [CI]: 0.69-0.95), 94% (95% CI: 0.88-1.0) and 93% (95% CI: 0.87-0.99).
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showing significant improvement in the BNP group over
controls [24]; a UK study in 306 primary care referrals
for suspected HF emphasising the high NPV of the
NT-proBNP assay (ECG had no additional predictive
value) [25]; and the prospective 600-patient N-terminal
PRo-BNP Investigation of Dyspnea in the Emergency
department (PRIDE) study which found the test with its
99% NPV to be a valuable addition to standard clinical
assessment for identifying and excluding acute HF: a
positive NT-proBNP was the strongest independent pre-
dictor of a final positive diagnosis of HF.
TE diagnosis
TE includes PE and DVT, which are closely interrelated
since 90% of symptomatic PE arise from leg vein
thrombi [26]. It’s well recognised that TE cannot
unequivocally be diagnosed from the history and physi-
cal examination alone, even in high-risk patients [27].
The recent development of non-invasive D-dimer blood
tests with a very high NPV has markedly enhanced the
accuracy of diagnosis [28].
In our study, the sensitivity, specificity and NPV of the
TE diagnoses were good in both groups, making it diffi-
cult to determine whether diagnoses in the POCT group
were more accurate. The D-dimer assay showed moder-
ate specificity but very high sensitivity and NPV. The
only patient with a false-negative D-dimer was a 65-year-
old man with a history of cancer who was correctly diag-
nosed with a DVT based on his symptoms. The NPV
confirmed the assay’s power in excluding TE. While a
negative D-dimer safely excludes TE, patients with a posi-
tive result should still be screened for PE and DVT, in
particular in the presence of typical symptoms. Our
results are consistent with those of other studies, e.g.
Leclercq et al. or Schutgens et al. [29,30].
Study limitations and future research
Some limitations of the study require discussion. For
example, we confined ourselves to Zurich County for
practical reasons; whether the results can or cannot be
extrapolated to less urbanised areas remains to be
determined.
A second limitation was patient recruitment. Initially,
recruitment was clearly higher in the POC group. We
put this down to a difference in study awareness: the
device on their premises made POCT physicians more
study-aware. Control physicians, on the other hand, had
only the study protocol and the questionnaires to
remind them, and perhaps forgot to recruit; after we
initiated regular telephone reminders, recruitment rates
became almost equal in both groups.
The follow-up diagnoses were another limitation. In
principle, they should have been performed by
independent blinded assessors but this was not feasible.
For practical and data protection reasons, they were
made by the same physician who was primarily con-
sulted by the patient. We are aware of the potential for
bias, e.g. due to possible underreporting of incorrect
baseline diagnoses leading to a false high rate of correct
baseline diagnoses or a false low difference between
study arms. On the other hand, for patients referred for
further diagnostic work-up (including all patients at
potentially high cardiovascular risk), GPs received a
written report on the second-stage assessment as well as
information on further clinical management, which sub-
stantially reduced the risk of bias.
A fourth limitation concerns possible underestimation
of the number of HF diagnoses in the controls. Not
only were there significantly more pre-existing HF diag-
noses in the POCT group, but the total number of
newly identified HF patients was also greater. We
assume that the POCT physicians used the NT-proBNP
value as diagnostic criterion to identify more patients
with NYHA class I-II HF. Indeed, early stages of HF are
often asymptomatic and difficult to identify without
accurate screening. Some patients with mild HF may
not have been diagnosed as a result, and this tendency
would have been stronger in the controls.
As shown in Table 5 which compares biomarker per-
formance in the POCT group to the working and con-
firmed diagnoses, it seems that in some cases the GP
decided to ignore the results of the biomarker tests. It is
unknown if there was a lack of confidence in the bio-
markers, if there was a problem with the interpretation
of the results, or if GPs gave more importance to physi-
cal findings, symptoms, and patient history. In any case,
this finding emphasises the importance of training and
continuing medical education.
Health-economic and cost-effectiveness studies of car-
diovascular risk stratification using POCT are rare.
Some studies have analysed the costs and benefits of a
single biomarker for a defined disease. Thus Nielsen et
al. [31] concluded that NT-proBNP testing in primary
care patients with dyspnoea halved the need for echo-
cardiographic screening. Gustafsson et al. [32] reported
that a normal NT-proBNP effectively ruled out left ven-
tricular systolic dysfunction in primary care patients
referred for echocardiography, thereby avoiding unne-
cessary further investigation. Siebert et al. [33] found
that NT-proBNP measurement improved patient out-
come, reduced echocardiography use by 58%, prevented
13% of hospitalisations and reduced hospital stay by
12%. Similar studies have been performed for other bio-
markers, but a more general evaluation is needed of the
possible benefits of POCT for ACS, HF and TE in pri-
mary care.
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Conclusions
This study found substantial benefit for POCT diagnosis
in cardiovascular risk stratification at the primary care
level. Non-invasive analysis of cTnT, NT-proBNP and
D-dimer produced more accurate diagnoses of ACS, HF
and TE in the POCT group. Given the potential for sub-
stantial health-economic savings, we plan a fuller inves-
tigation based on the clinical outcomes of this study.
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